Trending
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Helixgate Featured14 hours agoFDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect...
-
Capital, M&A & Industry Strategy17 hours agoOpentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI...
-
AI, Machine Learning & Computational Biology17 hours ago100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery,...
-
Helixgate Featured18 hours agoPostmarketing Requirements and Commitments: Searchable Database
Learn more about FDA's Postmarketing Requirements and Commitments Searchable Database.
-
Regulatory Intelligence & Drug Approvals18 hours agoFDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
FDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
-
Synthetic Biology, Genomics & Advanced Therapeutics20 hours agoNo Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT
Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference....
-
Capital, M&A & Industry Strategy21 hours agoSanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as...
-
Capital, M&A & Industry Strategy22 hours agoAnthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
-
Global Biotechnology & Pharmaceutical Markets23 hours agoS7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
International Council on Harmonisation - Safety
-
Capital, M&A & Industry Strategy1 day agoNew biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.
